Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11816749 | 0.88 | L3MBTL1 (0.32) | L3MBTL1KIF11TP53RXFP1ALDH1A1 | |
| SCHEMBL6999252 | 0.86 | CYP2C19 (0.33) | L3MBTL1TP53RXFP1MAPT | |
| SCHEMBL11819407 | 0.86 | LMNA (0.37) | L3MBTL1TDP1KIF11TP53RXFP1 | |
| SCHEMBL6997990 | 0.86 | DHODH (0.36) | SMN1; SMN2L3MBTL1PTGDR2TP53RXFP1 | |
| SCHEMBL6998078 | 0.85 | CYP2C19 (0.39) | TP53RXFP1GABRA1GABRG2GABRB3 | |
| SCHEMBL7958122 | 0.85 | MAPT (0.36) | L3MBTL1KIF11TP53RXFP1GABRA1 | |
| SCHEMBL8303813 | 0.85 | L3MBTL1 (0.50) | SMN1; SMN2L3MBTL1KIF11ALDH1A1MAPT | |
| SCHEMBL7001235 | 0.85 | CTSL (0.35) | L3MBTL1TP53RXFP1ALDH1A1MAPT | |
| SCHEMBL6996442 | 0.85 | MIF (0.41) | L3MBTL1TP53ALDH1A1MAPT | |
| SCHEMBL7956671 | 0.85 | TP53 (0.37) | TP53RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| EP-0946548-B1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6329392-B1 | ANTIALLERGENS | AVENTIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| EP-0946545-B1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| US-5977139-A | Carboxysubstituted cyclic carboxamide derivatives | HOECHST MARION ROUSSEL, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0777666-B1 | SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMA INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5861417-A | TACHYKININ RECEPTOR ANTAGONISTS USEFUL IN TREATING ASTHMA, COUGH, BRONCHITIS, PAIN | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| WO-1998027085-A1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027086-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0777666-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1996006094-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | SMN1; SMN2 4541/4885L3MBTL1 4839/4885TDP1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.